SEPN compared with RAPP: revenue, margins and what each company keeps, and the suppliers and customers both name

SEPNSepterna, Inc.

Mkt capRevenueRevenue

RAPPRapport Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

SEPNSepterna, Inc.

RAPPRapport Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

SEPN: latest quarter is a loss; flow not drawable. RAPP: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

SEPN, solidRAPP, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only SEPN 2

VRTXVertex Pharmaceuticals Incorporated ("Vertex")customer

—Novounlistedcustomer

Shared 0

No shared counterparties.

Only RAPP 3

—Janssen Pharmaceuticalunlistedsupplier

—NeuroPaceunlistedsupplier

—Tenacia Biotechnology (Hong Kong)unlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

SEPNSepterna, Inc.

43.98▼−2.76%· post 43.98

Mkt cap$2.0BRevenue$27MQ2 FY26Revenue$46MFY25

RAPPRapport Therapeutics, Inc.

25.06▲+3.50%· post 24.57

ClosedOct 30 '26

Mkt cap$1.2BRevenue$20MQ1 FY26Revenue—

Compare

ClosedOct 30 '26

SEPNSepterna, Inc.

RAPPRapport Therapeutics, Inc.

43.98▼−2.76%post 43.98

Price

25.06▲+3.50%post 24.57

$2.0B

Mkt cap

$1.2B

Q2 FY26$27M

Revenue

$20MQ1 FY26

FY25$46M

Revenue

—

SEPN43.98▼−2.76%vsRAPP25.06▲+3.50%ClosedOct 30 '26